These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 5754670)
1. Kinetics of the effect of 5(or 4)-(3,3-dimethyl-1-triazeno)-imidazole-4 (or 5) -carboxamide (NSC-45388) and 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196) on the reproductive integrity of cultured leukemia L1210 cells. Wilkoff LJ; Dulmadge EA; Dixon GJ Cancer Chemother Rep; 1968 Dec; 52(7):725-32. PubMed ID: 5754670 [No Abstract] [Full Text] [Related]
2. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196). Kline I; Woodman RJ; Gang M; Venditti JM Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657 [No Abstract] [Full Text] [Related]
3. Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5(or 4)-[3,3-bis( 2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196). Hoffman G; Kline I; Gang M; Tyrer DD; Venditti JM; Goldin A Cancer Chemother Rep; 1968 Dec; 52(7):715-24. PubMed ID: 5743709 [No Abstract] [Full Text] [Related]
4. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962). Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255 [No Abstract] [Full Text] [Related]
5. Effectiveness of antileukemic agents in mice inoculated with a leukemia L1210 variant resistant to 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196). Tyrer DD; Kline I; Gang M; Goldin A; Venditti JM Cancer Chemother Rep; 1969 Sep; 53(4):229-41. PubMed ID: 5384463 [No Abstract] [Full Text] [Related]
6. Comparative effects of the antitumor agents 5-(Dimethyltriazeno)-imidazole-4-carboxamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on cell cycle of L1210 leukemia cells in vivo. Shirakawa S; Frei E Cancer Res; 1970 Aug; 30(8):2173-90. PubMed ID: 5459764 [No Abstract] [Full Text] [Related]
7. Adaptation of a colorimetric determination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388) and 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) to blood. Field RB; Hoffman G; Waravdekar VS; Kline I Cancer Chemother Rep; 1969 Jun; 53(3):199-202. PubMed ID: 4980814 [No Abstract] [Full Text] [Related]
8. Enhanced response of leukemia (L1210) mice to combination chemotherapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) and 5-fluorouracil (NSC-19893). Kline I; Woodman RJ; Gang M; Waravdekar VS; Goldin A; Venditti JM Cancer; 1971 Jun; 27(6):1363-8. PubMed ID: 5088212 [No Abstract] [Full Text] [Related]
9. Comparative studies on the chemical stability and therapeutic effectiveness of water-insoluble 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) and its water-soluble hydrochloride against L1210 mouse leukemia. Woodman RJ; Kline I; Field RB; Gang M Cancer Chemother Rep; 1973; 57(4):383-91. PubMed ID: 4762437 [No Abstract] [Full Text] [Related]
10. Complete inhibition of mouse leukaemia L1210 by 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196). Shealy YF; Krauth CA Nature; 1966 Apr; 210(5032):208-9. PubMed ID: 5963361 [No Abstract] [Full Text] [Related]
11. Kinetics of the reduction in viability of cultured L1210 leukemia cells exposed to 5-azacytidine (NSC-102816). Lloyd HH; Dulmadge EA; Wilkoff LJ Cancer Chemother Rep; 1972 Oct; 56(5):585-91. PubMed ID: 4119906 [No Abstract] [Full Text] [Related]
12. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide. Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275 [No Abstract] [Full Text] [Related]
13. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide. Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315 [TBL] [Abstract][Full Text] [Related]
18. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A Proc Natl Acad Sci U S A; 1970 Aug; 66(4):1089-95. PubMed ID: 5273445 [TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man. van Eden EB; Falkson G; van Dyk JJ; van der Merwe AM; Falkson HC Cancer Chemother Rep; 1972 Feb; 56(1):107-47. PubMed ID: 5030803 [No Abstract] [Full Text] [Related]